Friday’s Highlights at Noon: Anthera Pharmaceuticals (ANTH), Organovo Holdings (ONVO), Sarepta Therapeutics (SRPT), Acelrx (ACRX), Stratasys (SSYS)

By Carrie Williams

So far Friday, June 28, NASDAQ is up 0.18% and the S&P is up 0.17%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Anthera Pharmaceuticals (ANTHResearch Report), Organovo Holdings (ONVOResearch Report), Sarepta Therapeutics (SRPTResearch Report), Acelrx (ACRXResearch Report) and Stratasys (SSYSResearch Report).

Anthera Pharmaceuticals is up 25.74% in midday trading to $0.07. Shares opened today at $0.05. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Organovo Holdings is up 17.86% in midday trading to $0.52. Shares opened today at $0.44. The company has a 52-week low of $0.37 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.50, marking a 241.30% potential upside from current levels. In a report issued on May 24, H.C. Wainwright analyst Ed Arce maintained a Buy rating on ONVO, with a price target of $1.50, which represents a potential upside of 241% from where the stock is currently trading. Separately, on May 23, Jones Trading’s Matthew Cross downgraded the stock to Hold .

Sarepta Therapeutics is up 14.29% in midday trading to $149.83. Shares opened today at $131.10. The company has a 52-week low of $95.21 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $202.08, marking a 54.14% potential upside from current levels. In a report issued on June 26, Robert W. Baird analyst Brian Skorney reiterated a Buy rating on SRPT, with a price target of $202, which implies an upside of 54% from current levels. Separately, on May 9, Oppenheimer’s Hartaj Singh assigned a Hold rating to the stock . Over the last 3 months, the insider sentiment on Sarepta Therapeutics has been negative based on 35 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Acelrx is up 10.33% in midday trading to $2.35. Shares opened today at $2.13. The company has a 52-week low of $1.99 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $8.10, marking a 280.28% potential upside from current levels. In a report issued on June 6, H.C. Wainwright analyst Ed Arce maintained a Buy rating on ACRX, with a price target of $9, which implies an upside of 323% from current levels. Separately, on May 9, Oppenheimer’s Leland Gershell assigned a Hold rating to the stock . In the last 30 days, insiders purchased $11.55K worth of ACRX shares. Over the last 3 months, the insider sentiment on Acelrx has been positive based on 36 corporate insider transactions. This sentiment is higher than the average sector sentiment of insiders.

Stratasys is up 10.22% in midday trading to $28.36. Shares opened today at $25.73. The company has a 52-week low of $17.06 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $23.00, marking a -10.61% potential downside from current levels. In a report issued on May 29, Piper Jaffray analyst Troy Jensen reiterated a Buy rating on SSYS. Separately, on May 7, B.Riley FBR’s Christopher Van Horn assigned a Hold rating to the stock and has a price target of $23.

Trending Stocks Based on Insider Activity >>